Few industries live and die by IP the way pharma does. A single molecule can take over a decade and enormous investment to bring to market and for most of that time, it isn’t earning anything back. The patent (and everything around it regulatory exclusivity, trademarks, trade secrets in manufacturing) is what makes that investment recoverable. Get the IP strategy wrong, and even a genuinely good drug can lose its commercial window before it ever turns a profit.
This blog walks through what’s patentable in pharma, how search and freedom to operate fit into drug development timelines, where innovation is concentrated right now, what else beyond the core patent needs protecting, and how a firm like PATHtoIP fits into that process.
What Makes a Pharmaceutical Invention Patentable
The Three Basic Tests
The same three tests are used in the same way as in other areas: being new, having an inventive step and being able to be used in industry.
What Typically Gets Filed
Pharma has its usual patterns of what gets submitted:
- New chemical entities (NCEs): a truly new active molecule
- New formulations: long-acting versions treatments that combine several drugs and new ways to deliver the medicine
- New processes: better or cheaper ways to create an existing drug
- New uses: a known molecule that is found to treat a different disease (common in drug repurposing)
- Biologics and biosimilars: patents that cover the biological molecule itself and also patents that cover the way it is made which is more important here than in small-molecule chemistry because biologics are much harder to make exactly the same
Formulation and “new use” patents are where pharma companies most often keep a product’s commercial life going after the original compound patent ends and where patent offices, especially, in India look at them most carefully.
Search and Freedom to Operate: Higher Stakes Here Than Most Fields
Patentability Search:
This is a search to see if a molecule, a special mix or a new use is really new before we spend a lot of time and money on it.
We need to know this before we start spending years on development.
Freedom to Operate:
FTO analysis is very important for companies that make biosimilar drugs. These companies can only sell a version of a drug when the patents of the original drug maker have expired or been successfully challenged in court.
If a company gets the timing wrong it can be a risk and they might get sued.
Because clinical trials cost a lot of money, big pharmaceutical companies usually do not make decisions until they have done a patentability search and an FTO analysis.
This is different from some industries where companies might just file a patent and then figure out who owns what later.
Pharmaceutical companies need to be careful and do their research first unlike some companies that might just go for it and hope for the best.
Patentability Search and Freedom to Operate analysis are crucial for companies like these and they always look into Patentability Search and Freedom to Operate before making big decisions.
India vs. the US: A Quick Comparison
| India | United States | |
| Governing law | Patents Act, 1970 | 35 U.S.C. (Patent Act), plus Hatch-Waxman framework |
| New form/use of known drug | Barred under Section 3(d) unless enhanced therapeutic efficacy is shown | Generally patentable if novel and non-obvious |
| Patent term extension | Not available | Available under Hatch-Waxman for regulatory delay |
| Generic entry pathway | Post-grant opposition, compulsory licensing provisions | Abbreviated New Drug Application (ANDA), Paragraph IV challenge |
Section 3(d) is the single most consequential provision in Indian pharma patent law, it’s the reason India has historically been harder ground for “evergreening” strategies like new salts, polymorphs, or isomers of existing drugs, unless real efficacy gains can be shown. It’s also why India remains a major hub for the generics industry. The US takes the opposite approach in one respect: Hatch-Waxman allows patent term extension to compensate for time lost during FDA regulatory review, which doesn’t have an equivalent in India.
Where Innovation Is Actually Happening
Biologics and Biosimilars
Increasingly central as more blockbuster small-molecule patents expire.
mRNA and Gene Therapy Platforms
A genuinely new patent landscape is still being shaped.
Drug Repurposing
New therapeutic uses for existing approved molecules, often faster and cheaper to bring to market.
Novel Drug Delivery Systems
Long-acting injectables, targeted delivery, improved bioavailability formulations.
A technology landscape or white space analysis is particularly valuable in pharma before committing to a research direction, since it can reveal whether a target or mechanism is already heavily patented by competitors, potentially years before a molecule is even in preclinical testing.
Protecting the Product from Every Angle
A drug is rarely protected by just one type of IP. Different parts of the same product usually need different tools, often all at once:
Patents
Patents protect the invention itself, the molecule, formulation, or process. Lipitor (atorvastatin), Pfizer’s cholesterol drug and one of the best-selling medications in history, is a textbook example, its patent expiry in 2011 is still one of the most studied “patent cliff” events in the industry, since generic competition erased billions in revenue almost overnight.
Trademarks
Trademarks protect the brand, separately from, and in addition to, the molecule’s patent. Tylenol is a good example: acetaminophen (the active ingredient) has been off-patent for decades, but Johnson & Johnson’s Tylenol trademark remains protected indefinitely and is still what most consumers recognize and trust over a generic alternative.
Trade Secrets
Trade secrets protect manufacturing know-how that stays hidden even after the drug reaches the market, the exact process conditions, purification steps, or scale-up methods used to produce it consistently. This is especially significant for biologics, where the manufacturing process itself can be nearly as hard to replicate as the molecule companies often keep fermentation and purification details as trade secrets rather than patenting them, since a patent would require disclosing the roadmap while offering only 20 years of protection in return.
Pharma trademark clearance carries an added layer most other industries don’t deal with: regulatory scrutiny specifically to avoid names that could be confused with other drugs, a patient safety issue as much as a branding one, and a step generic and branded companies alike have to clear before a name can be used.
How PATHtoIP Helps
Pharma innovation rarely needs just one of these services in isolation, most drugs move through several of them across their lifecycle. PATHtoIP supports pharma innovators across the full path:
- Patentability searches: to confirm novelty before committing years of clinical development to a molecule or formulation
- Freedom to Operate analysis: ahead of a launch, especially critical for generics and biosimilars timing their entry against originator patents
- Patent drafting and filing: for NCEs, formulations, new uses, and biologics, in India and internationally
- Trademark filing: for drug brand names and trade dress, accounting for the added regulatory scrutiny around name confusion
- Technology landscape and white space analysis: to flag whether a target or mechanism is already heavily patented before committing R&D resources to it
Frequently Asked Questions
Can a pharma company get more patent protection time to make up for the years spent on regulatory approval?
In the US, yes Hatch-Waxman allows for patent term extension to offset time lost during FDA review. India doesn’t have an equivalent provision.
Why is Section 3(d) such a big deal for pharma companies filing in India?
It blocks patents on new forms of already-known drugs (like new salts or polymorphs) unless the applicant can show real improvement in therapeutic efficacy not just a modified molecule. It’s the main legal barrier to “evergreening” in India.
When can a generic version of a drug legally launch?
Only after the originator’s relevant patents have expired, been invalidated, or in some cases through a launch-at-risk strategy while a patent challenge is still pending which carries its own legal risk.
Working on a new molecule, formulation, or use, and not sure where it stands? PATHtoIP can help you map the IP strategy reach out at info@pathtoip.com.
